Neurocrine Biosciences, Inc.
NBIX
$118.78
$1.911.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -8.78% | 0.90% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -8.78% | 0.90% | |||
| Cost of Revenue | 39.76% | -3.99% | |||
| Gross Profit | -30.64% | 3.27% | |||
| SG&A Expenses | -8.38% | 28.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.51% | 13.58% | |||
| Operating Income | -81.91% | -29.11% | |||
| Income Before Tax | -90.96% | -14.56% | |||
| Income Tax Expenses | -88.57% | -1.65% | |||
| Earnings from Continuing Operations | -92.34% | -20.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -92.34% | -20.57% | |||
| EBIT | -81.91% | -29.11% | |||
| EBITDA | -77.34% | -27.81% | |||
| EPS Basic | -92.32% | -19.70% | |||
| Normalized Basic EPS | -70.34% | -25.46% | |||
| EPS Diluted | -92.09% | -19.27% | |||
| Normalized Diluted EPS | -70.31% | -25.27% | |||
| Average Basic Shares Outstanding | -0.30% | -1.09% | |||
| Average Diluted Shares Outstanding | -0.39% | -1.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||